RBIZ 0.024   +0.004 +20.00% Updated: 09-23-2017 $RBIZ

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
224
RBIZ 0.024   +0.004 +20.00% Updated: 09-23-2017 $RBIZ
Last Trade: 9/22/2017 3:47:00 PM

Last 0.024   +0.004 +20.00%
Open 0.025
Previous Close 0.020
Day High / Low 0.035 / 0.017
Year High / Low - / -
Volume 1,067,265
Projected Volume 1067265 (396%)
# of Trades / Projected 50 / 50
Dividend / Yield - / -
Abnormal Activity NONE
Abnormal Volume ABNORMAL VOLUME
Gap NONE
Candle BEARISH
Volatility Today HIGH
Volatility Yesterday HIGH
Price Relativity
From 40 Day High 100%
From 80 Day High 80%
From 150 Day High 62%
From 40 Day Low 150%
From 80 Day Low 159%
From 150 Day Low 159%
Pivot Analysis
Price Pivot $ 0.030
Day Resistance 1 $ 0.030
Day Support 1 $ 0.020
Day Resistance 2 $ 0.040
Day Support 2 $ 0.010
Consolidations
Short Term NO
Medium Term NO
Long Term NO
Volume Indicators
20 Day Avg Vol 269,186
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 304,628
Today / 150 Day Avg Vol ABOVE
Abnormal Volume ABNORMAL VOLUME
William Volume Accumulation bearish
Volume Price Trend bearish
Momentum Indicators
10 Day Trend bearish
40 Day Trend bullish
100 Day Trend bearish
Stochastics neutral
RSI bearish
MACD bullish
Moving Average Indictors
15 Day Trend bullish
45 Day Trend bullish
100 Day Trend bullish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today HIGH
Volatility Index Yesterday HIGH
10 Day Volatility INCREASING
20 Day Volatility INCREASING
40 Day Volatility INCREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 3

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 5

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 5

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 4

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 6

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights Into December's Top Mobile and CTV Apps for Revenue

Updated Category News Views 170

Top Revenue Generating Mobile and CTV Apps for December 2024 The evolving landscape of mobile and Connected TV (CTV) applications continually captivates users and advertisers alike. As 2024 comes to a close, the spotlight shines on the highest-grossing apps in North America, specifically in the United States and Canada, revealing significant trends in user engagement and...

Continue Reading
LET Mining's Cloud Strategy for XRP: Earn Passive Income Today

Updated Category News Views 106

Introduction to LET Mining's New Approach LET Mining is making waves with its innovative strategy that leverages XRP for cloud mining. This fresh perspective has caught the attention of numerous XRP holders, sparking excitement about its long-term profit potential. As more users join the platform, LET Mining is focusing on refining its computing power allocation to...

Continue Reading
Understanding Recent Changes in American Intl Gr's Short Interest

Updated Category News Views 70

Understanding American Intl Gr's Short Interest Dynamics American Intl Gr (AIG) has recently seen a notable change in its short percent of float, which has decreased by 3.24% since the last report. This change reflects a current total of 10.23 million shares sold short, making up approximately 1.79% of all available shares for trading. With the current trading volume,...

Continue Reading
Exploring the Future of the Phosphate Market: Growth and Trends

Updated Category News Views 520

The Rising Phosphate Market: An Overview The phosphate market is experiencing remarkable growth, projected to soar to approximately $219.74 billion in the coming years, driven by an annual growth rate of 3.9%. This growth is closely linked to the rising global demand for agricultural fertilizers, which play a crucial role in providing essential nutrients for plants....

Continue Reading
Clene Inc. to Engage with Investors at Benchmark Conference

Updated Category News Views 108

Clene Inc. to Engage with Investors at Benchmark Conference Clene Inc. (Nasdaq: CLNN), a dynamic clinical-stage biopharmaceutical company, is making its mark in the healthcare industry by focusing on innovative solutions for neurodegenerative diseases. Their mission is clear: to enhance mitochondrial health and safeguard neuronal functions. With a commitment to tackling...

Continue Reading